Personalised or precise, when it comes to medicine does it make a difference? #ClinicSpeak #MSBlog
It's that time of year again; time for the European Charcot Foundation meeting in Baveno. The programme is below. I am scheduled to speak on 'Personalized Medicine' on Friday. I have never done a talk on this topic so it is down to the drawing boards; I need a set of new slides and some inspiration. The following is Wikipedia's definition:
'Personalized medicine is a medical procedure that separates patients into different groups—with medical decisions, practices, interventions and/or products being tailored to the individual patient based on their predicted response or risk of disease.'
I think it will be important to differentiate personalised medicine from precision medicine:
'Precision medicine (PM) is a medical model that proposes the customization of healthcare, with medical decisions, practices, and/or products being tailored to the individual patient.'
It's that time of year again; time for the European Charcot Foundation meeting in Baveno. The programme is below. I am scheduled to speak on 'Personalized Medicine' on Friday. I have never done a talk on this topic so it is down to the drawing boards; I need a set of new slides and some inspiration. The following is Wikipedia's definition:
'Personalized medicine is a medical procedure that separates patients into different groups—with medical decisions, practices, interventions and/or products being tailored to the individual patient based on their predicted response or risk of disease.'
I think it will be important to differentiate personalised medicine from precision medicine:
'Precision medicine (PM) is a medical model that proposes the customization of healthcare, with medical decisions, practices, and/or products being tailored to the individual patient.'
It would help me if you could give me some kind of steer or guidance from you. What does personalised medicine mean to you? Is the care you receive personalised? Am I missing the point is it about how your team engages with you, or is it about your treatment or management? Is the NHS's drive to care pathways and personalised care plans compatible with your understanding of personalised medicine? Should personalised medicine be delivered by a computer algorithms or humans? Is humanised medicine more important? Help! Thanks.
Program
The theme of this year’s Annual Meeting: Multiple Sclerosis' Treatment in Practice promises interesting debates amongst researchers and clinical practitioners.
The XXIV ECF Lecture will be given by Prof. Dr. Gilles Edan, Head of the Neuroscience Department Pontchaillou Hospital, Central University Hospital of Rennes, France.
The Scientific Committee of the 24th Annual Meeting: G. Comi (president), M. Clanet, G. Edan, F. Fazekas, H.P. Hartung, L. Kappos, H. Lassmann, J. Palace
Thursday November 24, 2016 | ||
10:15 – 10:45
|
Welcome Coffee
| |
10:45 – 11:45
|
Satellite Symposium EXCEMED - Excellence in Medical Education
| |
11:45 – 12:45
|
Industry-sponsored Symposium
| |
12:45 – 13:15
|
Light Lunch
| |
13:15 - 14:15
|
XXIV ECF Lecture
| |
DMD Treatment Approval for MS: 20 Years Later!
| ||
14:15 - 16:00
|
Session I: TARGETS FOR INTERVENTIONS
| |
B Cells Dependent Immune Mechanism as a Target for Intervention
| ||
Pathophysiology of MS Variants: Treatment Implications
| H. Lassmann | |
Cytokines: Still a Relevant Target for MS Treatment?
| R. Hohlfeld | |
The Blood-Brain Barrier in MS: a Target for Treatment?
| E. de Vries | |
Q&A and Discussion
| ||
16:00 - 16:30
|
Coffee Break and Live Stream Poster Presentations
| |
16:30 - 18:00
|
Session II: LESSONS FROM CLINICAL TRIALS
| |
Methodology Problems: Old and New Solutions
| P. S. Soerensen | |
What do we Learn from Treatment Failures
| ||
How to Compare Efficacy Profiles of Treatments (Meta-Analysis)
| M.P. Sormani | |
Q&A and Discussion
| ||
18:00 – 18:15
|
Coffee Break
| |
18:15 – 19:15
|
Industry-sponsored Symposium
| |
19:15 – 20:15
|
Welcome Cocktail
| |
Friday November 25, 2016 | ||
07:15 - 07:30
|
Light Breakfast and Coffee
| |
07:30 - 08:30
|
Industry-sponsored Symposium
| |
08:30 - 10:15
|
Session III: POST MARKETING STUDIES
| |
Methodological Aspects and Evidences
| M. Trojano | |
10 Year Prospective Observation UK Study
| ||
Safety and Tolerability
| M. Clanet | |
Adherence in MS
| T. Ziemssen | |
Q&A and Discussion
| ||
10:15 – 11:15
|
Coffee Break and Poster Viewing
| |
11:15 - 13:00
|
Session IV: IMPROVING ASSESSMENTS
|
Chair: L. Patrucco
|
Cognition and Fatigue
| IK. Penner | |
Wearable Devices for Remote Control
| ||
Patients Reported Outcomes
| ||
Q&A and Discussion
| ||
13:00 - 14:00
|
Lunch
| |
14:00 - 15:45
|
Session V: TREATMENT INDIVIDUALIZATION
| |
| Personalized Medicine | G. Giovannoni | |
MS Prognostic Aspects
| ||
Role of Omics
| M. Comabella López | |
Role of the Organization
| G. Comi | |
Q&A and Discussion
| ||
15:45 - 16:15
|
Coffee Break
| |
16:15 - 18:00
|
Session VI: MONITOR AND TREATMENT
| |
Assessment of Treatment Response
| ||
MRI Monitoring
|
C. Enzinger
| |
Neurophysiology Methods
| ||
Safety Monitoring
|
H. Wiendl
| |
Q&A and Discussion
| ||
18:00 – 18:15
|
Coffee Break
| |
18:15 – 19:15
|
Industry-sponsored Symposium
| |
Saturday November 26, 2016 | ||
08:30 - 10:15
|
Session VII: TREATMENT DECISIONS
|
Chair: D. Miller
|
Breaking Through Disease
| ||
Starting a Treatment
| ||
Stopping a Treatment
| ||
Sharing Decisions with Patients
| ||
Q&A and Discussion
| ||
10:15 - 10:45
|
Coffee Break
| |
10:45 - 12:00
|
Session VIII: MS TREATMENT IN WOMEN AND CHILDREN
| |
Effects of Treatment on Reproduction
| ||
Treatment Decisions before and during Pregnancy
| ||
MS Treatment during Puerperium and Lactation
| ||
Pediatric MS
| ||
Q&A and Discussion
| ||
12:00 - 12:30
|
Young Investigator Awards
| |
12:30 - 13:00
|
Concluding Remarks
| |
13:00 - 14:00
|
Lunch
| |